(NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in ...

Johns Hopkins scientists discovered a way to convert “immune-cold” tumors into “immune-hot” ones by activating key immune ...

Scientists at Virginia Tech's Fralin Biomedical Research Institute at VTC and their collaborators are exploring emerging ...

Advances in tissue-based technology in the past few years have created unprecedented opportunities to identify biomarkers of disease processes, especially within oncology by using multi-omics ...

Phase 2 peri-operative study of fianlimab + cemiplimab + chemotherapy versus cemiplimab + chemotherapy in resectable early-stage non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract ...

Over the past decade, the advent of immune checkpoint blockade (ICB) therapy has transformed cancer treatment. Unlike conventional cytotoxic and targeted therapies, immunotherapy leverages both the ...

Japanese scientists successfully eliminated cancer tumors using live bacteria, a new therapy that acts independently of the ...

Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, it is worth highlighting ...

SOX30-mediated activation of CXCL2 as promotor of PMN-MDSC recruitment and immunosuppressive microenvironment in TNBC. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

The stroma to tumor ratio potentially identifies higher risk bladder cancer tumors and might help guide immunotherapy. Bladder tumors with higher stromal content may have a more immunosuppressive ...